产品
编 号：F193771
分子式：C24H32N6O3
分子量：452.55
分子式：C24H32N6O3
分子量：452.55
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
结构图
CAS No: 1616392-22-3
产品详情
生物活性：
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma.
体内研究：
GSK3326595 (5 mg/kg, Intraperitoneal injection, three times a week for 9?weeks) 增加肝脏甘油三酯水平而不影响 LDL 受体敲除小鼠的动脉粥样硬化。GSK3326595 (25-50 mg/kg, Oral, once a day for 2?weeks) 增强抗程序性细胞死亡蛋白 1 (PD-1) 免疫检查点治疗 (ICT) 在髓细胞瘤转基因启动 (MYC-ON) 小鼠肝细胞癌 (HCC) 中的疗效。Animal Model:LDL receptor knockout mice
Dosage:5 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Did not alter atherosclerosis susceptibility.Increased hepatic triglyceride levels without changing the hyperlipidemia extent.Activated genes involved in fatty acid acquisition.
Animal Model:myelocytomatosis transgene turned on mice
Dosage:25 mg/kg, 50 mg/kg
Administration:Oral
Result:Significantly suppressed tumor growth at 50 mg/kg.Showed better therapeutic efficacy at 25 mg/kg.
体外研究：
GSK3326595 (10-100 nM, 24-72 h) 通过减弱 ACE2-RBD 相互作用抑制 SARS-CoV-2 刺突假病毒感染 HEK-293 细胞和 A549 细胞。GSK3326595 (100 nM, 12 h) 诱导腹腔巨噬细胞向IFN-γ 诱导的 M1 型极化。GSK3326595 (0.15-10 μM, 72 h) 诱导 MCL 细胞死亡。
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma.
体内研究：
GSK3326595 (5 mg/kg, Intraperitoneal injection, three times a week for 9?weeks) 增加肝脏甘油三酯水平而不影响 LDL 受体敲除小鼠的动脉粥样硬化。GSK3326595 (25-50 mg/kg, Oral, once a day for 2?weeks) 增强抗程序性细胞死亡蛋白 1 (PD-1) 免疫检查点治疗 (ICT) 在髓细胞瘤转基因启动 (MYC-ON) 小鼠肝细胞癌 (HCC) 中的疗效。Animal Model:LDL receptor knockout mice
Dosage:5 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Did not alter atherosclerosis susceptibility.Increased hepatic triglyceride levels without changing the hyperlipidemia extent.Activated genes involved in fatty acid acquisition.
Animal Model:myelocytomatosis transgene turned on mice
Dosage:25 mg/kg, 50 mg/kg
Administration:Oral
Result:Significantly suppressed tumor growth at 50 mg/kg.Showed better therapeutic efficacy at 25 mg/kg.
体外研究：
GSK3326595 (10-100 nM, 24-72 h) 通过减弱 ACE2-RBD 相互作用抑制 SARS-CoV-2 刺突假病毒感染 HEK-293 细胞和 A549 细胞。GSK3326595 (100 nM, 12 h) 诱导腹腔巨噬细胞向IFN-γ 诱导的 M1 型极化。GSK3326595 (0.15-10 μM, 72 h) 诱导 MCL 细胞死亡。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备